OFFER DEADLINE01/07/2020 11:00 - Europe/Brussels
EU RESEARCH FRAMEWORK PROGRAMMEH2020 / Marie Skłodowska-Curie Actions
ORGANISATION/COMPANYInternational Research Projects Office
DEPARTMENTPromotion and Advisory Unit
Professor Rosario M. Sanchez-Martin, from the Department of Medicinal and Organic Chemistry at the University of Granada, welcomes postdoctoral candidates interested in applying for a Marie Skłodowska-Curie Individual Fellowships (MSCA-IF) in 2020 at this University. Please note that applicants must comply with the Mobility Rule (more information: http://sl.ugr.es/0aNV).
Brief description of the institution:
The University of Granada (UGR), founded in 1531, is one of the largest and most important universities in Spain. The UGR has been awarded with the "Human Resources Excellence in Research (HRS4R)", which reflects the UGR’s commitment to continuously improve its human resource policies in line with the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers. The UGR is also a leading institution in research, located in the top 5/10 of Spanish universities by a variety of ranking criteria, such as national R&D projects, fellowships awarded, publications, or international funding.
UGR is one of the few Spanish Universities listed in the Shanghai Top 500 ranking (http://sl.ugr.es/0aw0). The Academic Ranking of World Universities (ARWU) places the UGR in 268th position in the world and as the 4th highest ranked University in Spain, reaffirming its position as an institution at the forefront of national and international research. From the perspective of specialist areas in the ARWU rankings, the UGR is outstanding in Documentation (ranked in the 36th in the world) or Food science technology (ranked 37th in the world), Mathematics and Computer Science (ranked among the top 76-100 in the world).
The UGR has 4 researchers at the top of the Highly Cited Researchers (HCR) list in the Computer Science area. With regard to broader subject fields, the UGR is ranked in 45th position in the universities worldwide in the discipline of Engineering. It is also well recognized for its web presence (http://sl.ugr.es/0a6i) taking 36th place in the top 200 Universities in Europe. Internationally, we bet decidedly by our participation in the calls of the Framework Programme of the European Union. For the duration of the last two Framework Programmes, the UGR has obtained a total of 66 projects, with total funding of 18.02 million euros, and for H2020, 80 projects with total funding around 20.6 million euros.
Brief description of the Centre/Research Group
NanoChemBio lab is located at the Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO). GENYO has been designed as a multidisciplinar space of excellence for research on the genetic basis of diseases, including cancer, as well as for validation of therapeutic and diagnostic tools, together with the influence of genetic inheritance in the body’s response to certain drugs. GENyO is located at the Health & Science Technological Park (PTS), which comprises a hospital, the Andalusian tissue bank, several research centres and SME incubator centres. GENyO is fully equipped with the latest generation material and counts with a cell-culture unit, a flow cytometry unit and imaging unit, bionformatic unit and genomic unit with highly qualify technician in each unit. The NanoChemBio research group (CTS987) is made up of 11 members (2 permanent doctors + 3 non-permanent doctors + 6 doctoral students) from different disciplines such as pharmacists, chemists, biologists, biochemists and biotechnologists, whose objective is the design and development of therapeutic and diagnostic strategies based on nanotechnology and dynamic chemistry with a clear objective of translation to the clinic.
- Selective antitumoral therapy and diagnosis based on the use of nanodevices.
- Integration of nanotechnology with dynamic chemistry for in situ nucleic acid detection_ Development of diagnostic probes. Chemical-based platforms for miRNA detection.
- Nanotechnology Platforms for selective delivery of therapeutic agents
- HTS Platforms for biological systems
- PCR-free Diagnostic Platforms for nucleic acid testing
- Solid phase synthesis Platform- preparation of peptide, nucleic acid mimics and peptidomimetics
- Biomaterial Platforms for developing SMART materials
- Preclinical evaluation Unit of nanomaterials
We have two main research lines in our research group:
One research line focussed in the integration of dynamic chemistry with nanotechnology in the development of several chemical diagnosis platform to detect and characterise nucleic acid and circulating biomarkers, such as circulating tumoral cells and miRNA and SNPs, to enable novel chemical tools for prognosis and diagnosis in cancer and infectious diseases. This line of research is focused on the implementation of liquid biopsy as a clinical diagnostic tool. Nowadays we are working in the implementation of these chemical diagnostic probes for detection of nucleic acid by mass cytometry as well as other reading platforms.
The second major goal of the group is to apply our know-how in both nanotechnology and chemical biology techniques to develop radical approaches for developing selective therapies against cancer. We have recently developed a theranostic nanodevice based on multifunctionalization protocols and we are working on the validation of this device for its translation to clinic. Nowadays we are also focussed in the development of nanoformulations for CART therapy.
For a correct evaluation of your candidature, please send the documents below to Professor Rosario M. Sanchez-Martin (firstname.lastname@example.org):
- Letter of recommendation (optional)
The responsibility for the hosting offers published on this website, including the hosting description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.